Disscussion on the treatment of type 2 diabetes mellitus with new hypoglycemic drugs after initial treatment failure
Objective To investigate the efficacy and safety of empagliflozin combined with linagliptin in the treatment of patients with type 2 diabetes mellitus who failed initial treatment.Methods A total of 196 patients with type 2 diabetes mellitus who were admitted to Tianjin Port Hospital from September 2018 to August 2020 were selected as the study subjects,and were divided into control group and observation group by random number table method,with 98 cases in each group.The control group was treated with metformin combined with repaglinide,and the observation group was treated with empagliflozin and linagliptin on the basis of metformin.The levels of fasting blood glucose(FBG),2 h postprandial blood glucose(2hPBG),glycosylated hemoglobin(HbA1c),clinical efficacy and the incidence of adverse reactions of patients in the two groups were compared.Results The levels of FBG,2hPBG and HbA1c in observation group were lower than those in control group,and the differences were statistically significant(P＜0.05).The total clinical effective rate of treatment in the observation group was 97.96％,which was higher than 88.78％in the control group,and the difference was statistically significant(x2=6.673,P＜0.05).The incidence of adverse reactions was 15.31％in the observation group,which was lower than 17.35％in the control group,and there was no statistically significang difference the two groups(x2=0.167,P＞0.05).Conclusion Patients with type 2 diabetes who failed initial treatment were treated with empagliflozin combined with linagliptin,which had significant clinical efficacy and could effectively reduce patients'blood glucose level with few adverse reactions and high safety.
NETL
NSTL
万方数据
